To ensure the quality and safety of medical services in primary healthcare institutions, China’s National Health Commission (NHC) and other relevant authorities issued a notice on 1 April 2026, outlining a three-year nationwide action.

Microplate-based automatic blood grouping analyzer Metis of Aikang MedTech Co., Ltd. (henceforth referred to as Aikang) received approval for marketing in 2015; and its MGT-based automatic blood grouping analyzer Aigel received approval for marketing in 2016.

Australian molecular diagnostics developer Genetic Signatures has signed a strategic partnership with lab automation solutions provider Tecan and in vitro diagnostic software developer Repado. Announced on Tuesday, the partnership aims to create a scalable suite of fully integrated syndromic infectious disease testing systems. Financial terms were not disclosed.

Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended June 27, 2025.

Shares of Oxford Nanopore Technologies jumped 16 percent on Monday after the company reported strong preliminary revenues for the first half of 2025.

Cardiovascular disease remains the leading cause of death worldwide. More than half a billion people around the world continue to be affected by cardiovascular diseases, which accounted for 20.5 million deaths in 2021 – close to a third of all deaths globally and an overall increase on the estimated 121 million CVD deaths.

The University of California, Los Angeles School of Dentistry and South Korean semiconductor firm Dongwoon Anatech said on Friday that they have inked a three-year agreement worth upward of $2.4 million for the development of saliva-based liquid biopsy technologies.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

One Biosciences, a French startup pursuing single-cell tumor RNA sequencing, said on Thursday that it has raised €15 million ($17.4 million) Series A financing.

President Donald Trump's proposed budget cuts to the National Institutes of Health would eventually result in fewer drugs on the market, the U.S. Congressional Budget Office said on Friday.

Fulgent Genetics announced on Thursday that it has obtained the CE-IVDR mark for its germline next-generation sequencing service.

Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2025.